Cost-effectiveness of Commercial or Traditional Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
Listen to this summary
The authors aimed to evaluate the cost-effectiveness of commercial, FDA-approved microbiota therapeutics compared to traditional fecal microbiota transplantation (FMT) via colonoscopy for managing recurrent Clostridioides difficile infection (rCDI). Their findings indicate that traditional FMT is the most cost-effective strategy, with an incremental cost-effectiveness ratio of $44,158, while commercial microbiota therapeutics are not cost-effective when donor-derived FMT is available. Overall, the study concludes that colonoscopic FMT remains the optimal approach for preventing subsequent rCDI episodes.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
View all →Jun 12, 2026 · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Clinical Impact of the BIOFIRE® FILMARRAY® Pneumonia Panel in the Veterans Affairs Healthcare System: A Difference-in-Differences Study
Jun 11, 2026 · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Oral Wash PCR Improves the Diagnosis of Pneumocystis Pneumonia in Immunocompromised Patients Without HIV: A Prospective Multicenter Study
More in Pediatrics
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Critical care medicine
Ethical Implications of the Slow Code: A Systematic Review of Ethics of Slow Codes in U.S. Hospitals
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
